Who owns Sunovion pharmaceuticals?
Sumitomo Dainippon Pharma
Sumitomo Dainippon Pharma America, Inc.
Sunovion/Parent organizations
Sunovion, a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., was formed following the merger of Sumitomo Dainippon Pharma’s two U.S.-based operations, Sepracor Inc. and Dainippon Sumitomo Pharma America, Inc.
Where is Sunovion Pharmaceuticals located?
It was originally located in Princeton, New Jersey and then re-located to Marlborough, Massachusetts. In addition to its headquarters location in Marlborough, Massachusetts, Sunovion has locations in London, England, Mississauga, Ontario Canada, and Fort Lee, New Jersey.
Is Sunovion a good company to work for?
Great company for working parents Sunovion really values their employees and ensure programs and policies are in place for work-life balance. They also have a mentor program which connects junior employees to more experienced senior members of the organization.
When did Sepracor become Sunovion?
2010
TO BECOME SUNOVION PHARMACEUTICALS INC. MARLBOROUGH, Mass., July 15, 2010 — Sepracor Inc.
What happened to Sepracor?
Just to get you all caught up: Dainippon Sumitomo Pharma bought Sepracor in 2009 using a legal entity named Aptiom, so now Sepracor is called Sunovion.
What is the stock symbol for sunovion?
SEPR
Ticker: SEPR Sunovion Pharmaceuticals Inc. is incorporated in the state of Delaware.
Who bought Sepracor?
Dainippon Sumitomo Pharma Co Ltd
BOSTON/TOKYO (Reuters) – Dainippon Sumitomo Pharma Co Ltd agreed on Thursday to buy U.S. drugmaker Sepracor Inc for $2.6 billion, giving the Japanese firm a big, local sales force in the world’s largest drugs market.
What drug company makes Lunesta?
See full prescribing information for LUNESTA. To report SUSPECTED ADVERSE REACTIONS, contact Sunovion Pharmaceuticals Inc. at 1-877-737-7226 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
What company makes Aptiom?
Aptiom (eslicarbazepine acetate) by Sunovion Pharmaceuticals Inc has been approved by the FDA as an adjunctive treatment of partial-onset seizures in adult patients. An estimated 2.2 million Americans are affected by epilepsy, with partial-onset seizures accounting for 60% of new epilepsy diagnoses.
Can I take 4 mg of Lunesta?
Dosing can be raised to 2 mg or 3 mg if clinically indicated. The total dose of Lunesta should not exceed 3 mg, once each evening immediately before bedtime. Elderly patients and patients with hepatic impairment should not be prescribed doses of more than 2 mg.
Is there a generic form of Lunesta?
Eszopiclone oral tablet is available as a generic drug and as a brand-name drug. Brand name: Lunesta. Eszopiclone comes only as a tablet you take by mouth. Eszopiclone is used in adults to treat insomnia (trouble falling asleep, staying asleep, or both).
Is there a generic brand for Aptiom?
Eslicarbazepine acetate is the generic (non-brand) brand for the seizure medicine Aptiom® (ap tee’ om) from Sunovion Pharmaceuticals.
Who is the parent company of Sunovion Pharmaceuticals?
Sunovion, a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., was formed following the merger of Sumitomo Dainippon Pharma’s two U.S.-based operations, Sepracor Inc. and Dainippon Sumitomo Pharma America, Inc.
Who are Sumitomo Dainippon and chemiphar Pharma?
Chemiphar and Sumitomo Dainippon Pharma Conclude Collaborative Research and Development Agreement and Option Agreement for Novel Antidepressant/Anxiolytic Candidate Compound “NC-2800” Comments Regarding Media Article on Our Company
What is Sumitomo Dainippon’s drug for type 2 diabetes?
Poxel and Sumitomo Dainippon Pharma Announce the Approval of TWYMEEG (Imeglimin hydrochloride) for the Treatment of Type 2 Diabetes in Japan Chemiphar and Sumitomo Dainippon Pharma Conclude Collaborative Research and Development Agreement and Option Agreement for Novel Antidepressant/Anxiolytic Candidate Compound “NC-2800”
How does Sunovion do good in the world?
“We are doing good in the community and doing good in the world and making people feel better.” “At Sunovion, we’re empowered to create our own career path.” We partner with leading patient advocacy organizations and participate in a wide variety of events that help to raise awareness and support educational and research programs.